Biomarkers in current use for detecting AD pathology are those reflecting Aβ deposition (reduced CSF Aβ levels and raised brain Aβ load) and markers of neurodegeneration (MRI atrophy, reduced glucose metabolism on FDG-PET, and raised CSF p-tau) [38]. This evidence concerns the gene MAPT and Alzheimer disease.